

Grifols chosen as one of the best companies to work for in Spain by Forbes

- The publication values positively Grifols' practices and policies in diversity and inclusion, training and development, as well as benefits and measures focused on the workforce's well-being
- In 2021, 60% of Grifols staff were women and by 2030 the company's goal is that women make up half of its senior management
- Grifols has dynamized its work environment with a new focus on flexibility, including a hybrid work model, flexible start and finish times and digital disconnection

Barcelona, Spain, May 4, 2022 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that it has been included in Forbes magazine's 2022 list of the 75 best companies to work for in Spain.

In a Forbes-commissioned survey of 250 Grifols employees in Spain, staff highlighted the company's positive progress in a range of areas related to worker experience, including diversity and inclusion, training and development, well-being and benefits.

With regards to diversity and inclusion, of the 23,324 people working in the company at the end of 2021, 60% were women. The company's goal is that by 2030 women make up 50% of its senior management. The number of workers in Spain with disabilities increased 11.4% last year. In 2021, Grifols began a three-year Diversity and Inclusion plan to continue driving advances in its workplace.

During the same year, the number of hours dedicated to training and development increased, exceeding 2.8 million.

As far as well-being, Grifols has implemented measures for its workers to better achieve work-life balance. Greater flexibility, including a hybrid work model, flexible start and finish times and digital disconnection, have dynamized the company's work environment. According to the results of the survey, staff also viewed positively other benefits such as flexible compensation, aid to families (awards for newborns, aid for education costs, etc.) and contributions to retirement accounts, among others.

"Grifols being chosen as one of the 75 best companies to work for in Spain shows that the road we're on is the right one," said Montse Gaja, Grifols Chief Human Resources Officer. "Given the constantly changing environment in which we're living it's important that Grifols continues to enhance flexibility, diversity and inclusion, in line with society's new demands and requirements."

GRIFOLS

Firm commitment to sustainability, also recognized internationally

Grifols' commitment to sustainability is firm. In January 2022 and for the second consecutive year, the company was included in the Bloomberg Gender-Equality Index (GEI), which values the practices and policies related to gender equality and diversity of listed companies.

Since December 2021, Grifols has formed part of the Dow Jones Sustainability World Index (DJSI). In 2020, it entered the DJSI Europe, Euronext Vigeo Europe 120 and the Euronext Vigeo Eurozone 120. Since 2018, it has been in the following stock market sustainability indexes: FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex.



MEDIA CONTACTS

International:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain:

Duomo Comunicación

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel. +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel. +34 650 402 225

About Grifols

Grifols is a global company in the health sector that has been working since 1909 to improve the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 110 countries.

A pioneer in the blood products industry, Grifols is one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it provides hospitals, pharmacies and health professionals with the tools, information and services that contribute to offering specialized and efficient medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that helps define the standards of continuous innovation, quality, safety and ethical leadership in the sector.

In 2021, Grifols' total economic impact in the main countries where it operates is estimated at 7,700 million euros and 141,500 jobs generated, including direct, indirect and induced jobs.

The company's ordinary shares (Class A) are listed on the Spanish Continuous Market and form part of the Ibex-35 (MCE: GRF). Grifols non-voting shares (Class B) are listed on the Spanish Continuous Market (MCE: GRF.P) and on the North American NASDAQ through ADR (American Depositary Receipts) (NASDAQ: GRFS).

For more information: www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.